Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis
IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin condition affecting 5%−20% of children and 2%−10% of adults worldwide. Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors (abrocitinib, upadacitinib). However, upper r...
Saved in:
| Main Authors: | Rose Alraddadi, Mulham Kalantan, Yara Aljefri, Hadeel Maaddawi, Abdulrahman Alsamadani, Athoub Kadasa, Abdulrahman Softah, Baraa Tabbakh, Rahaf Alturkistani, Abdulhadi Jfri |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1550640/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of topical minocycline preparations for papulopustular rosacea: a systematic review and meta-analysis
by: Awadh Alamri, et al.
Published: (2025-04-01) -
Case Report: Upadacitinib in the management of refractory urticarial vasculitis
by: Maan M. Almaghrabi, et al.
Published: (2025-08-01) -
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01) -
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study
by: Tiago Torres, et al.
Published: (2025-06-01) -
Real‑World Experience of 1 Year of Tralokinumab Treatment in Adult Patients with Atopic Dermatitis: A Single-Center Retrospective Study
by: Adrian O. Rodriguez, et al.
Published: (2025-06-01)